Cancer that develops in certain tissues such as the bone and muscle is a sarcoma. The main types of sarcoma are the bone and soft tissue sarcomas. Developing from soft tissues such as fat, muscle, blood vessels, nerves, deep skin tissues, and fibrous tissues, soft tissue sarcomas can be found in any part of the body and it has more than 50 types.
Survival rates, such as the stage 4 soft tissue sarcoma survival rate, are the standards or ways doctors use for discussing a patient’s prognosis. For example, the 5-year survival rate refers to the percentage of patients who live for at least five years after their cancer gets diagnosed.
Many people manage to live for more than five years and many get cured. On the other hand, five-year relative survival rates assume that some people die because of other reasons and compare the observed survival, with the survival expected for those without cancer. To get 5-year survival rates such as the stage 4 soft tissue sarcoma survival rate, doctors consider people who were treated at least five years ago. If the treatment has improved since then, chances are more favorable.
Be it for an earlier stage or a stage 4 soft tissue sarcoma, the survival rate is based on previous outcomes. Therefore, doctors cannot predict exactly what will happen in any individual’s case. A number of other factors, ranging from the location of the tumor, the type of sarcoma, and age of the patient to the treatment received, affect the survival rates. For example, sarcomas in arms and hands have better survival rates than other types of sarcomas found in other organs. Additionally, younger patients have better survival rates as compared to older patients.
When looking at survival rates, you should know that the stage doesn’t change over time even if cancer progresses. For example, if cancer spreads or comes back, it would be referred to as the stage that was given to it the very first time it was diagnosed. It is just that the treatment and information changes in accordance with the current extent of cancer.